BRPI1011721B1 - Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares - Google Patents

Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares Download PDF

Info

Publication number
BRPI1011721B1
BRPI1011721B1 BRPI1011721-0A BRPI1011721A BRPI1011721B1 BR PI1011721 B1 BRPI1011721 B1 BR PI1011721B1 BR PI1011721 A BRPI1011721 A BR PI1011721A BR PI1011721 B1 BRPI1011721 B1 BR PI1011721B1
Authority
BR
Brazil
Prior art keywords
dry
calcium
particles
less
dose
Prior art date
Application number
BRPI1011721-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean C. Sung
Michael M. Lipp
Original Assignee
Pulmatrix, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42635067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011721(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pulmatrix, Inc filed Critical Pulmatrix, Inc
Publication of BRPI1011721A2 publication Critical patent/BRPI1011721A2/pt
Publication of BRPI1011721B1 publication Critical patent/BRPI1011721B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1011721-0A 2009-03-26 2010-03-26 Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares BRPI1011721B1 (pt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US16376309P 2009-03-26 2009-03-26
US16377209P 2009-03-26 2009-03-26
US16376709P 2009-03-26 2009-03-26
US61/163,772 2009-03-26
US61/163,767 2009-03-26
US61/163,763 2009-03-26
US25576409P 2009-10-28 2009-10-28
US61/255,764 2009-10-28
US26774709P 2009-12-08 2009-12-08
US61/267,747 2009-12-08
US29809210P 2010-01-25 2010-01-25
US61/298,092 2010-01-25
US30581910P 2010-02-18 2010-02-18
US61/305,819 2010-02-18
PCT/US2010/028961 WO2010111680A2 (en) 2009-03-26 2010-03-26 Dry powder formulations and methods for treating pulmonary diseases

Publications (2)

Publication Number Publication Date
BRPI1011721A2 BRPI1011721A2 (pt) 2018-06-19
BRPI1011721B1 true BRPI1011721B1 (pt) 2021-11-16

Family

ID=42635067

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011721-0A BRPI1011721B1 (pt) 2009-03-26 2010-03-26 Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares

Country Status (15)

Country Link
US (3) US20120064126A1 (enExample)
EP (2) EP2410981B2 (enExample)
JP (2) JP5671001B2 (enExample)
KR (1) KR101639098B1 (enExample)
CN (2) CN102497853B (enExample)
AU (1) AU2010229668C1 (enExample)
BR (1) BRPI1011721B1 (enExample)
CA (1) CA2754691C (enExample)
DK (1) DK2410981T4 (enExample)
ES (1) ES2625260T5 (enExample)
IL (1) IL215276A (enExample)
MX (1) MX354829B (enExample)
PT (1) PT2410981T (enExample)
RU (1) RU2577698C2 (enExample)
WO (1) WO2010111680A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101639098B1 (ko) 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
WO2012058719A1 (en) * 2010-11-02 2012-05-10 The Universtity Of Sydney Inhalable compositions
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
BR112013029803B1 (pt) 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
US20140336159A1 (en) 2011-10-07 2014-11-13 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
NZ722952A (en) 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
JP2015509788A (ja) * 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
BR112015002270B1 (pt) * 2012-08-01 2020-02-11 Purac Biochem B.V. Pó de lactato e método para a preparação do mesmo
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10736840B2 (en) * 2013-09-03 2020-08-11 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017210658A1 (en) 2016-06-03 2017-12-07 Otitopic Inc. Dry powder formulations for inhalation
AU2017318672B2 (en) 2016-09-01 2022-03-10 Nutrition 21, Llc Magnesium biotinate compositions and methods of use
EP3846825A4 (en) 2018-09-05 2022-11-02 Sensory Cloud, LLC FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES
JP2022515314A (ja) 2018-11-02 2022-02-18 ニュートリション・２１，エルエルシー イノシトール安定化アルギニンケイ酸塩複合体及びイノシトールを含有するビデオゲームプレーヤーの認知機能を改善するための組成物
IL294021A (en) * 2019-12-16 2022-08-01 Nutrition 21 Llc Methods of production of arginine-silicate complexes
CN119013010A (zh) * 2021-12-16 2024-11-22 艾维尔勒斯生物公司 用于治疗慢性肺病的可吸入或可摄入的乳酸组合物
CN119894498A (zh) * 2022-09-02 2025-04-25 莉塔护理有限公司 用于治疗呼吸道感染的药物干粉组合物和方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
GB2265845B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
SK284448B6 (sk) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996032096A1 (en) 1995-04-14 1996-10-17 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6315983B1 (en) * 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
DE69928279T2 (de) * 1998-11-10 2006-08-17 Altana Pharma Ag Lungensurfactant zubereitungen enthaltendes behandlungset
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2383491A1 (en) † 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
EP1666028B1 (en) 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
CA2405811C (en) * 2000-04-12 2011-09-27 Altana Pharma Ag Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
CA2382133C (en) † 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
ATE378039T1 (de) 2000-06-27 2007-11-15 Vectura Ltd Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT2301524E (pt) 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
ES2415654T3 (es) * 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
EP1466610A4 (en) 2001-11-26 2007-03-21 Daiichi Asubio Pharma Co Ltd MEDICAL COMPOSITIONS FOR RECEIVING VIA THE NOSE
US20030232019A1 (en) 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
DK1531798T3 (da) 2002-03-20 2012-08-13 Civitas Therapeutics Inc Pulmonal frigørelse af Levodopa
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
CA2488976C (en) † 2002-06-28 2009-08-25 Advanced Inhalation Research, Inc. Inhalable epinephrine
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (zh) 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
EP1617834B1 (en) 2003-05-01 2006-09-27 Innogene Kalbiotech Pte. Ltd. Use of a pharmaceutical composition containing lactic acid or lactate and potassium for treating brain edema or brain injury
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
KR20050056622A (ko) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 플레쉬롬 다운로드 장치
US7192919B2 (en) * 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
WO2005094869A1 (en) 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
RU2007106714A (ru) 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
JP2008513444A (ja) * 2004-09-20 2008-05-01 コラス ファーマ インコーポレイテッド リドカイン及び他の局所麻酔剤の標的運搬並びに咳そう及び咳の発作の処置のための方法
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1888257A1 (en) 2005-05-05 2008-02-20 Pulmatrix, Inc. Ultrasonic aerosol generator
EP2308469A1 (en) * 2005-05-18 2011-04-13 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
GB0523576D0 (en) 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
DK2252275T3 (en) 2008-02-13 2018-03-05 Univ Texas CREATED NON-OPEN FLOCKS OF ANISOTROPIC PARTICLES FOR IMPROVED TRANSPORT INTO THE Lungs
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
KR101621986B1 (ko) 2008-05-15 2016-05-17 노파르티스 아게 플루오로퀴놀론의 폐 전달
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
JP2012522009A (ja) 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
WO2010111650A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
KR101639098B1 (ko) 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
ES2379775T3 (es) 2009-03-26 2012-05-03 Pulmatrix, Inc. Formulaciones farmacéuticas y métodos para tratar infecciones del aparato respiratorio
CN102448438A (zh) 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada

Also Published As

Publication number Publication date
JP5671001B2 (ja) 2015-02-18
US20150335573A1 (en) 2015-11-26
CN102497853B (zh) 2018-03-23
US20150196486A1 (en) 2015-07-16
DK2410981T3 (en) 2017-05-22
EP2410981B2 (en) 2020-02-26
US9238005B2 (en) 2016-01-19
PT2410981T (pt) 2017-05-25
AU2010229668A1 (en) 2011-10-06
JP2012522018A (ja) 2012-09-20
KR101639098B1 (ko) 2016-07-12
HK1165709A1 (en) 2012-10-12
CN102497853A (zh) 2012-06-13
KR20120003459A (ko) 2012-01-10
EP3184099A1 (en) 2017-06-28
RU2011137960A (ru) 2013-05-10
JP2015061873A (ja) 2015-04-02
US9119778B2 (en) 2015-09-01
DK2410981T4 (da) 2020-03-09
RU2577698C2 (ru) 2016-03-20
CN108434126B (zh) 2021-11-19
IL215276A (en) 2016-08-31
EP2410981B1 (en) 2017-03-15
MX354829B (es) 2018-03-22
ES2625260T5 (es) 2020-07-29
WO2010111680A2 (en) 2010-09-30
ES2625260T3 (es) 2017-07-19
WO2010111680A3 (en) 2011-02-03
US20120064126A1 (en) 2012-03-15
AU2010229668B2 (en) 2016-03-24
IL215276A0 (en) 2011-11-30
EP2410981A2 (en) 2012-02-01
JP5964939B2 (ja) 2016-08-03
CA2754691C (en) 2019-07-30
CN108434126A (zh) 2018-08-24
AU2010229668C1 (en) 2016-09-15
BRPI1011721A2 (pt) 2018-06-19
CA2754691A1 (en) 2010-09-30
MX2011009957A (es) 2012-01-27

Similar Documents

Publication Publication Date Title
AU2010229668B9 (en) Dry powder formulations and methods for treating pulmonary diseases
AU2010229668C1 (en) Dry powder formulations and methods for treating pulmonary diseases
EP2611438B1 (en) Dry powder formulations and methods for treating pulmonary diseases
EP2448571B1 (en) Respirably dry powder comprising calcium lactate, sodium chloride and leucine
HK1240113A1 (en) Dry powder formulations and methods for treating pulmonary diseases
HK1165709B (en) Dry powder formulations and methods for treating pulmonary diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.